CompletedPhase 4

Arterial pH and Total Body Nitrogen Balances in APD

United States8 participantsStarted 2003-09

Plain-language summary

This study will test the hypothesis that by slightly lowering the acidity of blood (or increasing the pH), dialysis patients utilize protein and amino acids more efficiently.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Men and women from any ethnic/racial group \< 65 years.
✓. Treatment with CPD for 6 months and current treatment with APD for at least one month.
✓. Hemoglobin of at least 11.0 g/dl.
✓. Stable dose of erythropoietin treatment for at least the preceding three months.
✓. Subjects with normal nutritional status to mild malnutrition:
✓. Serum albumin \> 3.3 g/dl
✓. Relative body weight of 90-120% of the NHANES II median body weight for a given height, age range, gender and frame size.
✓. A normalized protein equivalent of total nitrogen appearance (nPNA) \> 0.80 g/kg actual body weight/day at the time of screening.

Exclusion criteria

✕. History of active cancer other than basal cell carcinoma.
✕. Symptomatic severe ischemic heart disease, uncontrolled severe dysrhythmias, uncontrolled congestive heart failure, poorly controlled hypertension, severe musculoskeletal disease, arthritis or amputation of the lower extremities.
✕. Insulin requiring diabetes mellitus.
✕. Patients who received L-carnitine or anabolic hormones (other than erythropoietin) within the previous 6 months.
✕. Use of CaCO3 as phosphate binder.
✕. Severe lung or liver disease, uncontrolled asthma, active vasculitis.
✕. Severe chronic infection or any other acute or chronic inflammatory or catabolic illnesses (e.g., active tuberculosis, AIDS, osteomyelitis).
✕. Psychosis, inability to give informed consent, evidence that patient will not comply with study protocol.

What they're measuring

N-balances

Timeframe: 20 days

Trial details

NCT IDNCT00586131

SponsorLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-04

View on ClinicalTrials.gov More End-stage Renal Disease trials